Concord Drugs Ltd (538965) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 538965 | NSE: | Pharmaceuticals & Drugs | Small Cap

Concord Drugs Share Price

76 -1.30 -1.68%
as on 05-Dec'25 12:13

Concord Drugs Ltd (538965) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 538965 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Concord Drugs

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Concord Drugs stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
190.36
Market Cap:
101.8 Cr.
52-wk low:
26.1
52-wk high:
92.5

Is Concord Drugs Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Concord Drugs: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Concord Drugs Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 15.9%8.8%7.5%6.2%6.1%15.7%9.3%6%4.5%4.7%-
Value Creation
Index
0.1-0.4-0.5-0.6-0.60.1-0.3-0.6-0.7-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 50.757.551.848.151.351.45951.343.336.942
Sales YoY Gr.-13.4%-9.9%-7.2%6.8%0%14.8%-13%-15.7%-14.6%-
Adj EPS 2.50.20.40.50.40.71.810.40.30.4
YoY Gr.--91.1%86.4%26.8%-26.9%94.7%146%-47.3%-56.3%-28.6%-
BVPS (₹) 20.826.224.629.526.930.632.433.433.834.134.9
Adj Net
Profit
1.80.20.30.40.30.71.60.90.40.31
Cash Flow from Ops. 3.61.76.91.22.51.60.82.223.2-
Debt/CF from Ops. 5.59.128.23.9821.277.65.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -3.5%-6.4%-14.4%-14.6%
Adj EPS -20.9%-4.6%-45.2%-28.6%
BVPS5.7%4.9%1.7%0.9%
Share Price 1.2% 26.5% 30.8% 100%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
12.60.91.71.91.42.65.831.30.91.2
Op. Profit
Mgn %
16.49.68.87.66.56.39.58.58.510.29.9
Net Profit
Mgn %
3.50.30.60.90.61.32.71.710.81.3
Debt to
Equity
1.30.80.70.40.40.50.60.50.40.50
Working Cap
Days
263251474620416293241296348414181
Cash Conv.
Cycle
12810212914619921718921724228373

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Concord Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 0.4 0.4
TTM Sales (₹ Cr.) 42.2 45.1
BVPS (₹.) 34.9 34.9
Reserves (₹ Cr.) 33 33
P/BV 2.22 2.22
PE 190.36 176.81
From the Market
52 Week Low / High (₹) 26.10 / 92.52
All Time Low / High (₹) 11.68 / 92.52
Market Cap (₹ Cr.) 102
Equity (₹ Cr.) 13.2
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Concord Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Concord Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Concord Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales51575248515159514337
Operating Expenses 42524744484853474033
Manufacturing Costs161011101716161377
Material Costs24373431272727292721
Employee Cost 2322334443
Other Costs 1211117222
Operating Profit 8654336444
Operating Profit Margin (%) 16.3%9.6%8.8%7.6%6.5%6.3%9.5%8.5%8.5%10.2%
Other Income 0000000000
Interest 3222212222
Depreciation 3322112221
Exceptional Items 0000040000
Profit Before Tax 3110042111
Tax 1000011000
Profit After Tax 2000032100
PAT Margin (%) 3.4%0.3%0.6%0.8%0.6%6.4%2.7%1.7%1.0%0.8%
Adjusted EPS (₹)2.40.20.40.50.43.81.81.00.40.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 15191923232728313434
Share Capital 778899991010
Reserves 8121115151820222424
Minority Interest0000000000
Debt20151210101316151415
Long Term Debt12631142101
Short Term Debt89999914141414
Trade Payables10166643937533
Others Liabilities 85871675656
Total Liabilities 525610683585056575659

Fixed Assets

Gross Block27293131313536373739
Accumulated Depreciation12151719202123252628
Net Fixed Assets 15141412111313121112
CWIP 0000101122
Investments 0000000122
Inventories8111919161217181819
Trade Receivables25167148252123161413
Cash Equivalents 0000000000
Others Assets 415335428911
Total Assets 525610683585056575659

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 4271221223
PBT 3110042111
Adjustment 5343333333
Changes in Working Capital -4-12-2-1-5-4-2-2-0
Tax Paid -1-0-0-0-0-0-1-0-0-0
Cash Flow From Investing Activity 0-1-2-0-1-4-2-2-1-2
Capex 0-1-2-0-1-4-2-1-1-2
Net Investments 0000000-100
Others 00000-000-00
Cash Flow From Financing Activity -4-4-5-1-2220-1-1
Net Proceeds from Shares 0030100210
Net Proceeds from Borrowing -000-30-0-1-1-11
Interest Paid -3-2-2-1-1-1-1-2-2-2
Dividend Paid 0000000000
Others -1-2-63-14401-0
Net Cash Flow -0-3-00-00000-0

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)12.320.941.691.921.4113.065.7731.290.87
ROCE (%)15.98.847.496.176.0615.699.35.974.474.73
Asset Turnover Ratio0.951.060.640.510.730.951.110.910.770.64
PAT to CFO Conversion(x)2N/AN/AN/AN/A0.670.52N/AN/A
Working Capital Days
Receivable Days190131306454263164135139128132
Inventory Days506110414112510191124152186
Payable Days2111284446443548170785656

Concord Drugs Ltd Stock News

Concord Drugs Ltd FAQs

The current trading price of Concord Drugs on 05-Dec-2025 12:13 is ₹76.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Concord Drugs stood at ₹101.8.
The latest P/E ratio of Concord Drugs as of 04-Dec-2025 is 190.4.
The latest P/B ratio of Concord Drugs as of 04-Dec-2025 is 2.22.
The 52-week high of Concord Drugs is ₹92.52 and the 52-week low is ₹26.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Concord Drugs is ₹42.20 ( Cr.) .

About Concord Drugs Ltd

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×